FMP
Sera Prognostics, Inc.
SERA
NASDAQ
Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
10.03 USD
0.26 (2.59%)
About
ceo
Ms. Evguenia Lindgardt M.B.A.
sector
Healthcare
industry
Medical - Diagnostics & Research
website
https://seraprognostics.com
exchange
NASDAQ
Description
Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
CIK
0001534969
ISIN
US81749D1072
CUSIP
81749D107
Address
2749 East Parleys Way
Phone
801 990 0520
Country
US
Employee
55
IPO Date
Jul 15, 2021
Key Executives
